Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-007 in Patients with Sorbitol Dehydrogenase (SORD) Deficiency
2022-000491-18Phase 3Active
- Sponsor
- Applied Therapeutics, Inc.
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Charcot-Marie-Tooth disease type 2S (CMT2S) and peripheral neuropathy comparing Govorestat with Placebo (2 arms). Primary endpoint: 10-meter walk/run test (10MWRT). Started May 2022; status: active.
02
Drugs
govorestat
03
Conditions
Charcot-Marie-Tooth disease type 2S (CMT2S)peripheral neuropathy
Beyond the preview
Go deeper on 2022-000491-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000491-18.